Premium
The effect of a long‐acting somatostatin analogue (SMS 201–995) on intermediary metabolism and gut hormones after a test meal in normal subjects
Author(s) -
FUESSL H. S.,
BURRIN J. M.,
WILLIAMS G.,
ADRIAN T. E.,
BLOOM S. R.
Publication year - 1987
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1987.tb00632.x
Subject(s) - medicine , endocrinology , pancreatic polypeptide , motilin , peptide yy , gastric inhibitory polypeptide , somatostatin , hormone , gastrin , glucagon , peptide hormone , gastrointestinal hormone , butyrate , basal (medicine) , insulin , secretion , chemistry , neuropeptide , receptor , biochemistry , neuropeptide y receptor , fermentation
SUMMARY SMS 201–995 is an octapeptide analogue of somatostatin. The effect of a single subcutaneous (s.c.) injection of 50 μg SMS 201–995 on postprandial intermediary metabolism was investigated in normal subjects. In spite of a long‐lasting post‐prandial suppression of insulin secretion, there were no significant changes in the plasma concentration of alanine, glycerol, 3‐OH‐butyrate or lactate. However, SMS 201–995 impairs carbohydrate tolerance, probably due to inhibition of insulin secretion. Basal and post‐prandial plasma concentrations of the gut regulatory peptides pancreatic glucagon, motilin, pancreatic polypeptide, gastric inhibitory polypeptide, enteroglucagon, gastrin and peptide YY were suppressed up to 5 hours after subcutaneous administration of a single dose of SMS 201–995.